Point-of-care molecular diagnostic devices: An overview

Chi Lan Nguyen Vu, Jianxiong Chan, Marian Todaro, Stan Skafidas, Patrick Kwan

Research output: Contribution to journalReview ArticleOtherpeer-review

6 Citations (Scopus)

Abstract

Point-of-care molecular diagnostic devices are a rapidly expanding market. A variety of technologies are being developed for DNA detection and amplification, mostly aiming to detect pathogens. Of the two devices for detection of human genetic variations, both focus on CYP2C19 and have obtained regulatory approval. Most other devices have not obtained US FDA approval and are still undergoing clinical trials. Most, if not all, devices in development require equipment to which disposable test cartridges are placed. Thus, they may not fulfill FDA's definition of being 'simple'. There is a clear need to develop completely disposable devices that do not require equipment maintenance, and to detect other genetic variants predictive of disease susceptibility and drug response.

Original languageEnglish
Pages (from-to)1399-1409
Number of pages11
JournalPharmacogenomics
Volume16
Issue number12
DOIs
Publication statusPublished - 1 Jan 2015
Externally publishedYes

Keywords

  • Atlas io™
  • Gene Z
  • molecular diagnosis
  • Nanomix
  • Nanosphere Verigene<sup>®</sup>
  • point-of-care
  • QuantuMDx Q-POC™
  • SNP Dr
  • Spartan

Cite this